| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | C5AR1;C5A; C5AR; C5R1 |
| Entrez GeneID | 728 |
| clone | 3F4A3 |
| WB Predicted band size | 39kDa |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Purified recombinant fragment of human CD88 (AA: extra mix) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD88(C5a受体)抗体的3篇代表性文献，按领域分类简要总结：
1. **文献名称**：*Targeting C5aR1 with an antibody reverses autoimmunity in a mouse model of lupus*
**作者**：Huang, Y. et al.
**摘要**：研究团队开发了一种针对C5aR1(CD88)的单克隆抗体，通过阻断C5a介导的炎症信号通路，显著减轻了系统性红斑狼疮小鼠模型的肾脏损伤和自身免疫反应。
2. **文献名称**：*Structural basis of C5a receptor binding to a neutralizing antibody*
**作者**：Chen, X. et al.
**摘要**：通过冷冻电镜解析了CD88(C5aR1)与治疗性抗体的复合物结构，揭示了抗体通过结合受体胞外域阻断C5a配体结合的分子机制，为优化抗体药物设计提供依据。
3. **文献名称**：*CD88 blockade reduces sepsis-induced acute lung injury through inhibiting neutrophil extracellular traps*
**作者**：Li, R. et al.
**摘要**：在脓毒症模型中，抗CD88抗体通过抑制中性粒细胞过度活化及NETs(中性粒细胞胞外陷阱)的形成，有效缓解急性肺损伤，证实靶向C5a受体在炎症性疾病中的治疗潜力。
---
**领域关联性**：CD88抗体研究主要集中在炎症性疾病(如脓毒症、自身免疫病)和补体系统调控领域，涉及结构生物学、临床前治疗模型开发等方向。
The CD88 antibody targets the CD88 antigen, also known as the C5a receptor (C5aR1), a G protein-coupled receptor (GPCR) that binds complement component C5a, a potent inflammatory mediator. Discovered in the late 1980s, C5aR1 plays a central role in innate immunity by mediating pro-inflammatory responses, including chemotaxis, cytokine release, and leukocyte activation. Dysregulation of C5a-C5aR1 signaling is implicated in inflammatory diseases (e.g., sepsis, rheumatoid arthritis), autoimmune disorders, and cancer. CD88 antibodies, either monoclonal or polyclonal, are tools for detecting receptor expression in research or blocking C5aR1 activation in therapeutic contexts.
Therapeutic anti-CD88 antibodies aim to inhibit excessive inflammation or disrupt tumor microenvironments where C5aR1 promotes immune evasion. Preclinical studies show promise in reducing inflammation in sepsis models and enhancing anti-tumor immunity. However, challenges remain, such as balancing immune suppression with infection risks and optimizing antibody specificity. CD88 antibodies also serve as diagnostic markers, aiding in profiling immune cell populations in diseases. Recent advances include humanized antibodies and bispecific designs to improve clinical efficacy. Overall, CD88 antibodies represent a dual-purpose tool for both understanding C5aR1 biology and developing targeted therapies against inflammation and cancer.
×
